Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs.

Tribouillard-Tanvier D, Dos Reis S, Gug F, Voisset C, Béringue V, Sabate R, Kikovska E, Talarek N, Bach S, Huang C, Desban N, Saupe SJ, Supattapone S, Thuret JY, Chédin S, Vilette D, Galons H, Sanyal S, Blondel M.

PLoS One. 2008 May 14;3(5):e2174. doi: 10.1371/journal.pone.0002174.

2.

Protein folding activity of the ribosome (PFAR) -- a target for antiprion compounds.

Banerjee D, Sanyal S.

Viruses. 2014 Oct 23;6(10):3907-24. doi: 10.3390/v6103907. Review.

3.

Synthesis of conjugates of 6-aminophenanthridine and guanabenz, two structurally unrelated prion inhibitors, for the determination of their cellular targets by affinity chromatography.

Gug F, Oumata N, Tribouillard-Tanvier D, Voisset C, Desban N, Bach S, Blondel M, Galons H.

Bioconjug Chem. 2010 Feb 17;21(2):279-88. doi: 10.1021/bc900314n.

PMID:
20092293
4.

Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding.

Reis SD, Pang Y, Vishnu N, Voisset C, Galons H, Blondel M, Sanyal S.

Biochimie. 2011 Jun;93(6):1047-54. doi: 10.1016/j.biochi.2011.03.002. Epub 2011 Mar 17.

PMID:
21396977
5.
6.

The various facets of the protein-folding activity of the ribosome.

Voisset C, Saupe SJ, Blondel M.

Biotechnol J. 2011 Jun;6(6):668-73. doi: 10.1002/biot.201100021. Epub 2011 May 12. Review.

PMID:
21567961
7.

Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost α2-adrenergic receptor agonistic activity.

Nguyen PH, Hammoud H, Halliez S, Pang Y, Evrard J, Schmitt M, Oumata N, Bourguignon JJ, Sanyal S, Beringue V, Blondel M, Bihel F, Voisset C.

ACS Chem Neurosci. 2014 Oct 15;5(10):1075-82. doi: 10.1021/cn5001588. Epub 2014 Sep 22.

PMID:
25244284
8.

Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy.

Barbezier N, Chartier A, Bidet Y, Buttstedt A, Voisset C, Galons H, Blondel M, Schwarz E, Simonelig M.

EMBO Mol Med. 2011 Jan;3(1):35-49. doi: 10.1002/emmm.201000109.

9.

Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions.

Tribouillard-Tanvier D, Béringue V, Desban N, Gug F, Bach S, Voisset C, Galons H, Laude H, Vilette D, Blondel M.

PLoS One. 2008 Apr 23;3(4):e1981. doi: 10.1371/journal.pone.0001981.

10.

Tools for the study of ribosome-borne protein folding activity.

Voisset C, Thuret JY, Tribouillard-Tanvier D, Saupe SJ, Blondel M.

Biotechnol J. 2008 Aug;3(8):1033-40. doi: 10.1002/biot.200800134. Review.

PMID:
18683165
11.

The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition.

Pang Y, Kurella S, Voisset C, Samanta D, Banerjee D, Schabe A, Das Gupta C, Galons H, Blondel M, Sanyal S.

J Biol Chem. 2013 Jun 28;288(26):19081-9. doi: 10.1074/jbc.M113.466748. Epub 2013 May 14.

12.

Spectroscopic and DFT studies on 6-aminophenanthridine and its derivatives provide insights in their activity towards ribosomal RNA.

Banerjee D, Vovusha H, Pang Y, Oumata N, Sanyal B, Sanyal S.

Biochimie. 2014 Feb;97:194-9. doi: 10.1016/j.biochi.2013.10.012. Epub 2013 Oct 30.

PMID:
24184272
13.

The double life of the ribosome: When its protein folding activity supports prion propagation.

Voisset C, Blondel M, Jones GW, Friocourt G, Stahl G, Chédin S, Béringue V, Gillet R.

Prion. 2017 Mar 4;11(2):89-97. doi: 10.1080/19336896.2017.1303587. Review.

PMID:
28362551
14.

The toll-like receptor agonist imiquimod is active against prions.

Oumata N, Nguyen PH, Beringue V, Soubigou F, Pang Y, Desban N, Massacrier C, Morel Y, Paturel C, Contesse MA, Bouaziz S, Sanyal S, Galons H, Blondel M, Voisset C.

PLoS One. 2013 Aug 16;8(8):e72112. doi: 10.1371/journal.pone.0072112. eCollection 2013.

15.

Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation.

Blondel M, Soubigou F, Evrard J, Nguyen PH, Hasin N, Chédin S, Gillet R, Contesse MA, Friocourt G, Stahl G, Jones GW, Voisset C.

Sci Rep. 2016 Sep 16;6:32117. doi: 10.1038/srep32117.

16.

Antiprion drugs as chemical tools to uncover mechanisms of prion propagation.

Tribouillard D, Gug F, Galons H, Bach S, Saupe SJ, Blondel M.

Prion. 2007 Jan-Mar;1(1):48-52. Epub 2007 Jan 20. Review.

17.

Isolation of drugs active against mammalian prions using a yeast-based screening assay.

Bach S, Talarek N, Andrieu T, Vierfond JM, Mettey Y, Galons H, Dormont D, Meijer L, Cullin C, Blondel M.

Nat Biotechnol. 2003 Sep;21(9):1075-81. Epub 2003 Aug 10.

PMID:
12910243
18.

Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.

Bertsch U, Winklhofer KF, Hirschberger T, Bieschke J, Weber P, Hartl FU, Tavan P, Tatzelt J, Kretzschmar HA, Giese A.

J Virol. 2005 Jun;79(12):7785-91.

19.

Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles.

Nguyen P, Oumata N, Soubigou F, Evrard J, Desban N, Lemoine P, Bouaziz S, Blondel M, Voisset C.

Eur J Med Chem. 2014 Jul 23;82:363-71. doi: 10.1016/j.ejmech.2014.05.083. Epub 2014 Jun 3.

PMID:
24927056
20.

Supplemental Content

Support Center